Rarefied drug pricing

Your saved search

Your RSS Feed

Editorial

. 2014 May;32(5):398.

doi: 10.1038/nbt.2912.

No authors listed

Editorial

No authors listed. Nat Biotechnol. 2014 May.

. 2014 May;32(5):398.

doi: 10.1038/nbt.2912.

No abstract available

Similar articles

Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE. John JE. Drug Discov Today. 2011 Dec;16(23-24):999-1000. doi: 10.1016/j.drudis.2011.10.004. Epub 2011 Oct 14. Drug Discov Today. 2011. PMID: 22020052 No abstract available.
Uncommon ventures launch to tackle uncommon diseases.
Dolgin E. Dolgin E. Nat Med. 2013 Aug;19(8):950-1. doi: 10.1038/nm0813-950. Nat Med. 2013. PMID: 23921728 No abstract available.
New models for pharmaceutical innovation in low-income countries.
Ardal C, Iversen JH, Myhr K. Ardal C, et al. Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658. Tidsskr Nor Laegeforen. 2011. PMID: 22016131 English, Norwegian. No abstract available.
[From drug cost to drug price: steps and decisional processes].
Bruyninckx M, Nourissier C. Bruyninckx M, et al. Presse Med. 2012 May;41 Suppl 1:S40-3. doi: 10.1016/j.lpm.2012.02.016. Epub 2012 Apr 8. Presse Med. 2012. PMID: 22487715 French. No abstract available.
[Cohorts and registers: Which public/private partnerships to choose?].
Jouan-Flahault C, Landais P, Thomas R, Parker S, Genevaz D. Jouan-Flahault C, et al. Presse Med. 2012 May;41 Suppl 1:S15-9. doi: 10.1016/j.lpm.2012.02.023. Epub 2012 Mar 30. Presse Med. 2012. PMID: 22464892 French. No abstract available.